Corvus Pharmaceuticals, Inc. — Director's Dealing 2016

Mar 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2016-03-29

Reporting Person: LEA LEIV (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-29	Common Stock, $0.0001 par value	C	42608	—	Acquired	199253	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-29	Series A Preferred Stock	$	C	42608	Disposed		Common Stock (42608)	Indirect

Footnotes

F1: The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering.

F2: A portion of these shares is subject to a right of repurchase held by the Issuer.

F3: These shares are held by Leiv Lea and Deborah Karlson, Trustees of the Karlson Lea Family Trust UTA dated February 11, 1998 (the "Karlson Lea Trust"). Mr. Lea has shared voting, investment and dispositive power over the shares held by the Karlson Lea Trust.

F4: The expiration date is not relevant to the conversion of these securities.